Product Description
BPT323 Selectively Activates Tregs with no Activity on CD8+ T cells. BPT263 site-specifically conjugated to Fc region of antiTNFalpha mAb adalimumab. It is an immunocytokine for treatment of autoimmune diseases combining orthogonal modes of action of TNFalpha blockade and selective Treg expansion. (Sourced from: https://brightpeaktx.com/wp-content/uploads/2022/10/Poster-BPT-323.pdf)
Mechanisms of Action: TNF Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bright Peak Therapeutics
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|